LUNAR IIIb Study Comparing Rosuvastatin and Atorvastatin in Subjects With Acute Coronary Syndromes

A 12-week Randomized, Open-label 3-arm, Parallel Group, Multicenter Phase IIIb Study Comparing Efficacy and Safety of Rosuvastatin 20mg and 40mg With That of Atorvastatin 80 mg in Subjects With Acute Coronary Syndromes

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00214630

Enrollment

825

Registered

2005-09-22

Start date

2003-12-31

Completion date

2007-08-31

Last updated

2010-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndromes

Brief summary

Comparison of rosuvastatin and atorvastatin in subjects with acute coronary syndromes

Interventions

DRUGrosuvastatin calcium

DRUGatorvastatin

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Non-ST segment elevation ACS and ST segment elevation ACS who receive optimal reperfusion therapy

Exclusion criteria

* Previous Q-wave infarct within the last 4 weeks * CK elevation not caused by myocardial injury * uncontrolled hypertension at time of randomization

Design outcomes

Primary

Measure	Time frame
Reduction of LDL-C following 12 weeks of treatment	—

Secondary

Measure	Time frame
% change from baseline in LDL-C following 2 & 6 weeks of treatment; % change from baseline in TC, HDL-C, triglycerides, non-HDL-C, apolipoprotein A-1, apolipoprotein B, LDL-C/HDL-C, TC/HDL-C, non-HDL-C/HDL-C, ApoB/Apo A-1 @ weeks 6 & 12	—

Countries

Costa Rica, El Salvador, Morocco, Panama, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026